GlobalData on MSN19d
Arbor to advance gene editing treatments with $73.9m fundingTCGX and ARCH Venture Partners spearheaded the funding ... paving the way for high-precision genome editing. Arbor is currently progressing the therapy through a multi-centre, open-label, Phase I/II ...
Series C led by ARCH Venture Partners and TCGX with significant participation from existing and new investors Financing extends Arbor’s cash runway into 2027 and supports the clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback